Paul Hartmann AG's ROE % for the quarter that ended in Dec. 2025 was 7.89%. Paul Hartmann AG's PB Ratio for the quarter that ended in Dec. 2025 was 0.69.
Paul Hartmann AG's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 11.43%.
Paul Hartmann AG ROE % Adjusted to Book Value Related Terms
Paul Hartmann AG ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Paul Hartmann AG's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paul Hartmann AG ROE % Adjusted to Book Value Chart
STU:PHH2 vs ISRG, BDX, MDLN: ROE % Adjusted to Book Value Comparison
For the Medical Instruments & Supplies subindustry, Paul Hartmann AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paul Hartmann AG ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Paul Hartmann AG's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Paul Hartmann AG's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 11.43% mean?
Paul Hartmann AG (STU:PHH2) has a ROE % Adjusted to Book Value of 11.43% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Paul Hartmann AG and its competitors.
Is Paul Hartmann AG's ROE % Adjusted to Book Value too high?
Paul Hartmann AG's current ROE % Adjusted to Book Value is 11.43%. Overall, Paul Hartmann AG has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Paul Hartmann AG's ROE % Adjusted to Book Value compare to ISRG and BDX?
Paul Hartmann AG's ROE % Adjusted to Book Value of 11.43% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Paul Hartmann AG and its competitors. Paul Hartmann AG's current ROE % Adjusted to Book Value is 11.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paul Hartmann AG stock overvalued right now?
Based on GuruFocus' analysis, Paul Hartmann AG (STU:PHH2) is currently considered Fairly Valued. The stock's GF Value™ is €225.24, compared to a current price of €204.00 — trading 9.4% below its estimated fair value. The current ROE % Adjusted to Book Value is 11.43%. Paul Hartmann AG's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Paul Hartmann AG (STU:PHH2), the current ROE % Adjusted to Book Value is 11.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paul Hartmann AG (STU:PHH2) Overvalued in 2026?
Based on GuruFocus' analysis, Paul Hartmann AG stock appears to be undervalued.
The current stock price of €204.00 is trading 9.4% below its estimated GF Value™ of €225.24.
GuruFocus considers Paul Hartmann AG to be Fairly Valued.
Key valuation signals for STU:PHH2:
ROE % Adjusted to Book Value: 11.43%
GF Value™: €225.24 vs. price of €204.00 (9.4% below fair value)
No single metric tells the full story. See the STU:PHH2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.
61GF Score
Get the complete analysis for STU:PHH2
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PHH2 has been successfully added to your 
